NSE · GLENMARK
Glenmark Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,435 Cr with net profit ₹736 Cr — a 30.21% net margin, versus 7.81% the period before.
Shareholding
As of 2026-06-30
- Promoter46.65%
- Public13.85%
- FII20.89%
- DII18.6%
2,11,418 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.42× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #9 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,41,910 Cr | 34.98 | 5.29 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,12,010 Cr | 22.94 | 4.13 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,030 Cr | 30.74 | 3.2 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,06,566 Cr | 97.45 | 20.11 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹97,933 Cr | 30.4 | 2.57 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹96,387 Cr | 25.49 | 2.54 | 9.25% | 10.7% |
| Lupin Limited | ₹96,072 Cr | 16.13 | 4.28 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹93,873 Cr | 44 | 5.76 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd.(this company) | ₹68,496 Cr | 21.95 | 6.52 | 28.08% | 10.22% |
| Biocon Ltd. | ₹64,023 Cr | 87.69 | 1.86 | 1.14% | 2.89% |
AI analysis
AI-generated · google/gemini-2.5-flashGlenmark Pharmaceuticals Ltd. is listed with a market capitalization of Rs 63199 Cr. The company reported revenue of Rs 13435.46 Cr and a net profit margin of 8.15%. Its earnings per share (EPS) stood at Rs 104.59.
Positives
- +The company's revenue growth was 12.8%.
- +Return on Equity (ROE) is 28.08%.
- +Return on Capital Employed (ROCE) is 32.70%.
- +The debt-to-equity ratio is 0.22, indicating a low debt level.
- +Promoter pledge is 0%, indicating no shares are pledged.
Negatives
- −The P/E ratio is 209.69.
- −The net profit margin is 8.15%.
- −Net profit decreased to Rs -73.9 Cr in Mar 2026 from Rs 330.23 Cr in Jun 2025.
- −Net profit for the quarter ending Sept 2025 was Rs -739.19 Cr.
- −Number of shareholders increased from 83553 in Sep 2016 to 211418 in Jun 2026.
Financial Performance
As of Mar 2025, Glenmark Pharmaceuticals Ltd. recorded revenue of Rs 13435.46 Cr. The company's revenue growth was 12.8%. For the same period, the net profit was Rs 1047.10 Cr, resulting in an EPS of Rs 37.11. The EBITDA for Mar 2025 was Rs 1979.09 Cr.
Profitability & Returns
Glenmark Pharmaceuticals Ltd. achieved a return on equity (ROE) of 28.08% and a return on capital employed (ROCE) of 32.70%. The company's profit margin stood at 8.15%. In Mar 2026, the company reported a net profit of Rs 301.41 Cr from a revenue of Rs 3770.59 Cr for the quarter.
Balance Sheet
The company has a debt-to-equity ratio of 0.22, indicating a low level of debt relative to its equity. The book value per share is Rs 372.5, demonstrating the company's underlying asset value per share.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Glenmark Pharmaceuticals Ltd. is 46.65%. Public shareholding accounts for 13.85%. There are no promoter pledges reported, with a pledge percentage of 0%.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Glenmark Pharmaceuticals Ltd.share price & fundamentals